CardioDx, a company developing cardiovascular genomic diagnostics, has raised $60 million in new equity funding. New investors Longitude Capital, J.P. Morgan, Acadia Woods Partners, Artiman Ventures, and Bright Capital, the venture arm of RU-COM, participated in the round, which also included the company’s previous investors. The company has raised money previously from Kleiner, Perkins, Caufield & Byers, Mohr Davidow Ventures, TPG Biotech, Intel Capital, Pappas Ventures, DAG Ventures, Asset Management Group and GE Capital. Funding will be used to expand reimbursement coverage in the United States for the company’s blood-based gene expression test for obstructive coronary artery disease, as well as to continue development of future products. The company, based in Palo Alto, Calif., closed a $45 million round in May 2010.